| |
n
|
Sitagliptin treatment group
|
n
|
Conventional treatment group
|
Adj. mean difference (95% CI)
|
p value between-group
|
|---|
|
Mean GSM-CCA (weeks)
|
|
Baseline
|
137
|
50.6 ± 18.6
|
136
|
52.6 ± 18.3
| |
0.36
|
|
52
|
130
|
51.1 ± 17.9
|
126
|
52.0 ± 17.6
| |
0.66
|
|
104
|
120
|
52.6 ± 16.9
|
122
|
53.5 ± 20.3
| |
0.69
|
|
Mean change (SE) (weeks)
|
|
52
| |
0.65 (1.11)
| |
0.25 (1.14)
|
0.40 (− 2.74, 3.53)
|
0.80
|
|
104
| |
2.40 (1.19)*
| |
1.32 (1.19)
|
1.08 (− 2.23, 4.39)
|
0.52
|
|
Right GSM-CCA (weeks)
|
|
Baseline
|
136
|
51.3 ± 20.6
|
136
|
52.8 ± 18.9
| |
0.53
|
|
52
|
129
|
51.2 ± 19.1
|
126
|
53.1 ± 18.8
| |
0.41
|
|
104
|
120
|
53.2 ± 18.2
|
122
|
53.4 ± 20.6
| |
0.94
|
|
Mean change (SE) (weeks)
|
|
52
| |
0.14 (1.30)
| |
1.26 (1.32)
|
− 1.13 (− 4.77, 2.53)
|
0.54
|
|
104
| |
2.39 (1.38)
| |
0.85 (1.37)
|
1.53 (− 2.30, 5.36)
|
0.43
|
|
Left GSM-CCA (weeks)
|
|
Baseline
|
136
|
49.9 ± 19.9
|
136
|
52.5 ± 21.2
| |
0.30
|
|
52
|
130
|
50.9 ± 19.4
|
126
|
50.9 ± 19.5
| |
0.99
|
|
104
|
120
|
51.9 ± 19.0
|
122
|
53.6 ± 22.2
| |
0.52
|
|
Mean change (SE) (weeks)
|
|
52
| |
1.12 (1.38)
| |
− 0.46 (1.40)
|
1.58 (− 2.29, 5.45)
|
0.42
|
|
104
| |
2.08 (1.48)
| |
2.12 (1.48)
|
− 0.04 (− 4.17, 4.09)
|
0.98
|
|
Right GSM-plaque (weeks)
|
|
Baseline
|
74
|
51.4 ± 19.5
|
65
|
55.8 ± 21.5
| |
0.21
|
|
52
|
72
|
51.7 ± 19.3
|
56
|
55.6 ± 22.9
| |
0.30
|
|
104
|
61
|
53.5 ± 20.4
|
62
|
59.2 ± 23.6
| |
0.16
|
|
Mean change (SE) (weeks)
|
|
52
| |
2.06 (2.04)
| |
2.80 (2.23)
|
− 0.74 (− 6.77, 5.28)
|
0.81
|
|
104
| |
5.49 (2.69)*
| |
4.20 (2.71)
|
1.29 (− 6.30, 8.88)
|
0.74
|
|
Left GSM-plaque (weeks)
|
|
Baseline
|
80
|
52.6 ± 23.5
|
77
|
55.4 ± 20.9
| |
0.43
|
|
52
|
76
|
51.2 ± 19.4
|
69
|
54.5 ± 20.5
| |
0.32
|
|
104
|
73
|
54.5 ± 21.3
|
73
|
51.9 ± 17.5
| |
0.42
|
|
Mean change (SE) (weeks)
|
|
52
| |
1.15 (2.19)
| |
− 0.05 (2.24)
|
1.20 (− 5.01, 7.41)
|
0.70
|
|
104
| |
5.10 (2.50)*
| |
− 0.35 (2.57)
|
5.45 (− 1.66, 12.56)
|
0.13
|
- The primary outcome of this study was the change of Mean GSM-CCA (sown in italics). Data are mean ± SD unless otherwise stated
- Comparisons of GSMs during treatment with those at baseline were performed with one-sample t-test based on a mixed-effects model for repeated measures. Differences in Δchange in GSM from baseline at 52 and 104 weeks between groups were analyzed with a mixed-effects model for repeated measures. Treatment group, week, interactions between treatment group and week, and baseline GSM were included as fixed effects
- CI confidence interval, GSM gray-scale median, CCA common carotid artery, SE standard error
- * p < 0.05
